Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11296722 | 0.90 | ALDH1A1 (0.54) | LMNASMN1; SMN2POLBTDP1MAPT | |
| SCHEMBL11891940 | 0.90 | ALDH1A1 (0.54) | LMNASMN1; SMN2POLBTDP1MAPT | |
| SCHEMBL11296725 | 0.90 | ALDH1A1 (0.54) | LMNASMN1; SMN2POLBTDP1MAPT | |
| SCHEMBL12836563 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2POLBTDP1CES2 | |
| SCHEMBL987066 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2POLBTDP1CES2 | |
| SCHEMBL987065 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2POLBTDP1CES2 | |
| SCHEMBL20028184 | 0.85 | LMNA (0.51) | LMNASMN1; SMN2POLBTDP1CES2 | |
| SCHEMBL8937459 | 0.84 | TDP1 (0.49) | SMN1; SMN2TDP1MAPTALDH1A1HPGD | |
| SCHEMBL10397671 | 0.83 | LMNA (0.49) | LMNASMN1; SMN2POLBTDP1CES2 | |
| SCHEMBL10397670 | 0.83 | LMNA (0.49) | LMNASMN1; SMN2POLBTDP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1749522-A2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| EP-1640359-A2 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1042275-B1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMA INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030199589-A1 | Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses | NPS PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-6617358-B1 | Also bis(optionally chloro- or fluoro-substitutedphenyl)alkylcarboxy acids and esters | NPS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6306912-B1 | POLYAMINO CARBONYLAMINO ALKYL FLUORO SUBSTITUTES INDOLE COMPOUNDS | NPS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1123922-A2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6071970-A | FOR TREATING PATIENTS HAVING NEUROLOGICAL DISEASE OR DISORDER, SUCH AS STROKE, HEAD TRAUMA, SPINAL CORD INJURY, EPILEPSY, ANXIETY, OR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PARKINSON'S DISEASE | NPS PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6051610-A | COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS | NPS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199589-A1 | Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses | GABRE, GABRA2, GABRB2 | LMNA 501/4885SMN1; SMN2 127/4885POLB 2564/4885 |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | LMNA 723/4885SMN1; SMN2 84/4885POLB 2211/4885 |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | LMNA 723/4885SMN1; SMN2 84/4885POLB 2211/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | LMNA 176/4885SMN1; SMN2 7/4885POLB 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.